AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference
March 02 2021 - 4:01PM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
(LAA) management, today announced that the company will be
participating in the upcoming Oppenheimer 31st Annual Healthcare
Conference.
AtriCure’s management is scheduled to present on Tuesday, March
16, 2021, at 1:10 p.m. Eastern Time. Interested parties may access
a live and archived audio webcast of the presentation by visiting
the “Investors” section of the company’s website at
https://ir.atricure.com.
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first and only
medical device to receive FDA approval for the treatment of
persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage
Exclusion System products are the most widely sold LAA management
devices worldwide. For more information, visit AtriCure.com or
follow us on Twitter @AtriCure.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210302006057/en/
Angie Wirick AtriCure, Inc. Chief Financial Officer (513)
755-5334 awirick@atricure.com
Lynn Pieper Lewis Gilmartin Group Investor Relations (415)
937-5402 lynn@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Apr 2023 to Apr 2024